Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ADLT, Agarwal, alleviate, Anna, autosomal, BARC, benign, Bio, biosimilar, BRCA, Brian, capture, Cerba, chance, chemistry, chemotherapeutic, children, chrRCC, clarifying, combat, combatting, CY, destroy, destroyed, dominant, EBITDA, edit, effector, Eisai, Ernst, ethical, feedback, Fisher, FY, Giuliano, GlaxoSmithKline, Hematopathology, hope, hourly, Huntsman, hypothetical, immune, immunomodulatory, infiltrate, inherited, Invitae, judicial, KidneyPath, Knowledgebase, lender, MolDx, Monday, Moonshot, MSKCC, Nant, Neeraj, OC, officially, Oncomine, Opko, ordinarily, passage, PFG, PhRMA, placement, positon, Pref, prepay, reconciling, redemption, reportedly, resected, Rita, rulemaking, satisfactory, Shaknovich, show, Shuch, sixteen, SNP, soft, Stutent, subordinated, SummationTM, syndrome, text, Thermo, Trump, underway, undetermined, unrestricted, unused, Utah, wave, Young
Removed:
abbreviated, accelerating, accomplished, adequacy, affiliated, AG, Agilent, anaplastic, Andrew, animal, arbitration, architecture, assisting, attributable, biology, bore, Brazil, Bridge, broaden, bundle, charter, Clara, Coleman, Columbia, comparison, consummation, contingently, counsel, CPI, crizotinib, Daily, Dako, DAM, demonstrating, developmental, distinguished, effected, Electric, element, entry, exchanged, expiration, extension, fall, founded, founder, freely, gathering, GE, Genentech, Genzyme, geopolitical, HercepTest, Herceptin, Iceland, implantable, incremental, ISO, issuable, Jonathan, Julie, Kamineni, kinase, lapsing, LIBOR, Liechtenstein, maximum, menu, migrating, milestone, moderate, modification, Mt, NJCCA, NNJCA, nonclinical, novo, Oman, operated, OTC, outsourced, overallotment, oversee, packaging, pathway, pattern, Pecora, Pfizer, platform, pose, preclinical, predicate, predictability, preeminent, presence, priced, printing, prognostication, prolonged, promissory, promoted, promotional, proportion, Qiagen, reclassified, recognizable, recur, reforming, relevancy, renewed, repaid, responder, retroactively, reverse, Rosetta, SA, Santa, Secondary, Sergei, Sinai, split, strike, sum, supplement, supplemental, surrendered, Syrbu, termination, tool, transparency, trastuzumab, truthful, unscheduled, USA, user, vemurafenib, vendor, vested, workflow, Zelboraf
Filing tables
Filing exhibits
VYNT similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-191520, 333-191521, 333-196198, 333-205903 and 333-214599), on Form S-3 (No.333-196374) and on Form S-1 (No. 333-215284) of Cancer Genetics, Inc. of our report dated March 23, 2017, relating to the consolidated financial statements of Cancer Genetics, Inc. and Subsidiaries appearing in the Annual Report on Form 10-K of Cancer Genetics, Inc. for the year ended December 31, 2016.
/s/ RSM US LLP
New York, New York
March 23, 2017